This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

trusted source

proofread

Printing plant-based pharmaceuticals—without plants

Printing plant-based pharmaceuticals—without plants
Members of the University of Rochester's iGEM team used bacteria cultures, pictured here frozen in liquid nitrogen, to make 3D-bioprinted bacteria samples as part of their project to replicate chemicals found in plants. Credit: University of Rochester photo / J. Adam Fenster

Rochester undergraduates have developed a 3D-bioprinting system to replicate chemicals found in plants, including those endangered by climate change.

Imagine a world without plants. Although this extreme scenario has not become a reality, Earth is facing a concerning trend—the rapid depletion of potential plant-derived drugs. Globally, tens of thousands of flowering plant species play vital roles in medicinal applications, but many of the pharmaceuticals dominating the United States market heavily rely on imported raw plant materials that require very particular climate conditions for optimal growth.

The threat to many plant species is intensified by factors such as , invasive pests and diseases, and farming practices struggling to meet the large demand for end products.

To address these problems, a team of 10 University of Rochester undergraduate students pioneered new technologies to more efficiently replicate useful chemicals found in plants, including those endangered by Earth's changing climate. Calling themselves "Team RoSynth," the students created an affordable 3D-printing system for optimizing production of in-demand, plant-derived drugs and pharmaceuticals.

In November, the team entered their research in the 2023 International Genetically Engineered Machine (iGEM) competition, an event in which student-led teams from around the globe compete to solve real-world problems using synthetic biology. Synthetic biology takes advantage of engineering to build biological parts inspired by nature. The Rochester team's project was nominated for the Best Biomanufacturing Project and Best Hardware and was awarded a gold medal, making them the third most recognized team in the United States. The team competed against 402 teams from six continents.

"Team RoSynth's technology has huge potential to push forward the entire field of , allowing for straightforward, accessible production of new engineered living materials," says Anne S. Meyer, an associate professor in the Department of Biology and one of the advisors for Rochester's iGEM team.

An 'ingenious' method of bioprinting hydrogels

Team RoSynth designed their 3D bioprinter to print hydrogels—jelly-like substances made of water and polymers that can hold and release biological molecules. The Rochester team's system is unique because it prints genetically engineered bacteria and genetically engineered yeast in adjacent hydrogels, which are then submerged in a liquid nutrient broth. The complex work of making the final product chemical is divided among the two different types of microbes, making the process go more easily and quickly.

A key innovation lies in the fact that the yeast and the bacteria need to grow separately to prevent one microbe from growing faster and causing the slower-growing microbe to die off; however, the two microbes also need to be able to exchange molecules to build up the final product chemical.

"To solve this tricky problem, the students devised an ingenious solution," Meyer says. "The yeast and the bacteria were 3D bioprinted in hydrogels, so the microbes were kept separate from each other, but the molecules they produced could exchange freely."

The approach results in the synthetic creation of plant-based chemicals, without the need for actual plants.

As a test case, the team biochemically synthesized rosmarinic acid (RA). RA is typically extracted from plants such as rosemary, sage, and fern. It is used as a flavoring and in cosmetics and has also been shown to have antioxidant and anti-inflammatory properties. While rosmarinic acid is not itself endangered, it was an ideal extract to test.

"Rosmarinic acid is a valued plant compound but was not toxic or hazardous to the students to produce," Meyer says. "Plus, the pathway to make it is pretty complex, consisting of a large number of enzymes that act sequentially."

A response to climate change

The team, which is completely student-led with several faculty members on hand as advisors, began brainstorming project ideas at the beginning of 2023. Inspired by the COVID-19 pandemic, climate change, and Rochester's location near agricultural hubs in New York, the team prioritized addressing climate impacts on supplies of plant-based chemicals.

"Since we are located in Rochester, which is adjacent to the Finger Lakes region, a major agricultural area in New York State, we thought about how the impact of climate change will lead to decreasing crop yields over the coming years and impact local supplies of plants and plant-based compounds," says Catherine Xie, a major.

Printing plant-based pharmaceuticals—without plants
The bioprinted bacteria created by Rochester undergraduates contains green fluorescent proteins that glow under ultraviolet light. Credit: University of Rochester photo / J. Adam Fenster

Medha Pan, also a molecular genetics major, adds, "Our iGEM team was focusing on the climate crisis and agricultural shortages that we have been facing, especially in the COVID era. We have seen firsthand the importance of having accessible and reliable medication."

Examples of specific drugs that might benefit from the methods and technologies developed by Team RoSynth include aspirin, which is derived from willow tree bark, and the cancer drug taxol, developed by species of yew trees that have been identified as needing protection.

An affordable bioprinter

Part of the team's mission was to a create an affordable bioprinter with an open-source design to empower others to explore synthetically creating plant-based chemicals.

"A typical bioprinter will cost over $10,000, but we engineered one under $500," says Allie Tay, a biomedical engineering major. "We wanted to have a 3D bioprinter that would be accessible for labs to do this proof of concept with whichever molecules they choose."

The project is such that other scientists can change the genes and the engineered pathways in the bacteria and yeast to produce virtually any plant-based chemical. The design of the bioprinter itself is available on the team's Wiki page and includes a guide on how to build and use the printer so others can create and adapt the technology for a variety of uses.

Blending nature with cutting-edge technology, the team proved that undergraduates can lead groundbreaking projects in record time.

"Projects like these usually take years for Ph.D. or grad students to develop," Tay says, "and the fact that we're undergrads doing this and we were given from February to November—I think that's a pretty big undertaking."

Citation: Printing plant-based pharmaceuticals—without plants (2024, February 5) retrieved 27 April 2024 from https://phys.org/news/2024-02-based-pharmaceuticals.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Scientists identify biosynthetic pathway of chemotherapeutic derived from yew trees

78 shares

Feedback to editors